Huahai Pharmaceuticals" raw material change production process supplement application approved

Huahai Pharmaceuticals said the approval marks the company's ability to sell the drug in the domestic market, further enriching the company's product line and helping to enhance the market competitiveness of the company's productsHuahai Pharmaceuticals' shattan tablets were approved by the State Drug Administration in 2018/5/30, and as a result of the adoption of a consistency evaluationHowever, on 7/5/2018, the European Medicines Agency announced that the carcinogen impurity NDMA had been detected in the raw material sassatan produced by The sea pharmaceutical industry in ChinaSince then, the European Medicines Agency and the FDA have issued recalls and warningsIn 2018/7/30, the National Health and Reform Commission issued a notice that all types of medical institutions at all levels shall not use pharmaceutical sassatan raw materials containing Huahai Pharmaceuticals involved in the recall of diseasesthe incident has damaged Huahai Pharmaceutical's business and reputationIn 2018, Huahai Pharmaceutical's sales of raw materials and intermediates fell 6.23% year-on-year, while net profit attributable to shareholders of listed companies fell 81.05 percent year-on-year, the lowest level in nearly six yearsis mainly used to treat light and moderate primary hypertensionUpon enquiry, in 2018, the global market sales of the products of the fentanyl preparations (including tablets, capsules and other dosage forms) amounted to about US$4.5634 billion, and the sales of the domestic public medical institutions of the tablets (including tablets and dispersible tablets) amounted to about US$1.01 billionUp to now, Huahai Pharmaceuticals has invested about 18.36 million yuan in research and development projects in the research and development projectHuahai Pharmaceuticals released the 2019 results forecast shows that the 2019 net profit attributable to shareholders of listed companies is expected to increase by 405 to 50 million yuan compared with the same period last year, an increase of about 376% to 465 percent year-on-yearNet profit attributable to shareholders of listed companies, net less non-recurring profit and loss, is expected to increase by 275 to 370 million yuan in 2019 compared with the same period last year, an increase of about 240% to 323% YoY.